Skip to main content
MNRO
NASDAQ Trade & Services

Monro's Annual Report Reveals Mixed Financials, Credit Facility Reduction, and Major Restructuring Amid Strategic Review

Analysis by Wiseek AI
Sentiment info
Neutral
Importance info
9
Price
$17.29
Mkt Cap
$497.126M
52W Low
$12.255
52W High
$23.91
Market data snapshot near publication time

Summary

Monro, Inc.'s annual report details a mixed financial performance with improved GAAP net income but reduced operating cash flow, alongside a significant store restructuring and further amendments to its credit facility to ease covenants. This comprehensive financial update provides critical context for the company's recently announced strategic review, including a potential sale.


Key Events

  • Fiscal Year 2026 Financial Performance

    Net income improved to $2.2 million from a $5.2 million loss in the prior year, but adjusted diluted EPS declined to $0.42 from $0.48. Sales decreased 3.2% due to closed stores, partially offset by a 1.4% increase in comparable store sales. Operating cash flow significantly declined to $70.4 million from $131.9 million in the prior year.

  • Sixth Amendment to Credit Facility

    On May 21, 2026, the company entered into a Sixth Amendment to its Credit Facility, permanently reducing the facility from $500 million to $400 million. The amendment further eases financial covenants, reducing the minimum interest coverage ratio from 1.55x to 1.25x and the minimum liquidity requirement for dividends and acquisitions from $300 million to $200 million. Share repurchases remain prohibited if debt is outstanding.

  • Major Store Restructuring Completed

    The company closed 145 underperforming stores in the first quarter of fiscal 2026. This restructuring generated $19.7 million from selling 26 owned stores (net gain of $9.9 million) and $5.6 million from assigning/terminating 68 leases (net gain of $12.2 million), resulting in a net gain of $7.3 million recorded in operating expenses.

  • Shareholder Rights Plan Adopted

    A limited-duration shareholder rights plan (poison pill) was adopted on November 9, 2025, with a 17.5% trigger, set to expire on November 6, 2026. This defensive measure is intended to protect shareholder interests.


Analysis

This 10-K provides the full financial context for Monro's current operational challenges and strategic direction. The company reported improved GAAP net income but a decline in adjusted EPS and a significant drop in operating cash flow, indicating ongoing financial pressures. The sixth amendment to its credit facility, reducing its size and easing covenants, highlights the need for financial flexibility amidst these challenges. The substantial store closure plan, while generating some gains, reflects a major restructuring effort. The adoption of a shareholder rights plan (poison pill) and the concurrent announcement of a strategic review (from recent filings context) underscore a critical period for the company, with potential for significant corporate actions.

At the time of this filing, MNRO was trading at $17.29 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $497.1M. The 52-week trading range was $12.26 to $23.91. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MNRO - Latest Insights

MNRO
May 27, 2026, 8:29 AM EDT
Filing Type: 10-K
Importance Score:
9
MNRO
May 27, 2026, 8:18 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
MNRO
May 27, 2026, 7:44 AM EDT
Filing Type: 8-K
Importance Score:
9
MNRO
Mar 11, 2026, 4:01 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
MNRO
Feb 24, 2026, 4:08 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
8
MNRO
Jan 29, 2026, 5:15 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
8
MNRO
Jan 28, 2026, 8:31 AM EST
Filing Type: 10-Q
Importance Score:
7
MNRO
Jan 28, 2026, 7:34 AM EST
Filing Type: 8-K
Importance Score:
7